Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
44 hedge funds and large institutions have $669M invested in Centessa Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 8 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
3.01% more ownership
Funds ownership: 79.95% → 82.96% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
6% less funds holding
Funds holding: 47 → 44 (-3)
17% less capital invested
Capital invested by funds: $808M → $669M (-$139M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$16.8M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$11.9M |
| 3 |
OMC
OUP Management Company
Bala Cynwyd,
Pennsylvania
|
+$5.43M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.12M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$3.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$6.53M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$4.5M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.9M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$3.23M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| – | -$6K | -496 | Closed |
|
|
PHK
52
Point72 Hong Kong
Hong Kong
| – | +$73 | +8 | New |
|
CNTA Hedge Fund Activity: Q1 2022 in Review
44 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2022, worth a combined $669M — down 17% from $808M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CNTA and 5 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 16 added.
The largest buyer was Medicxi Ventures Management, adding an estimated $16.8M. The largest seller was VR Adviser, cutting an estimated $6.53M.
- 44 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2022, down from 47 in Q4 2021.
- Funds reported $669M of Centessa Pharmaceuticals stock for Q1 2022, down 17% quarter-over-quarter.
- 5 funds opened new Centessa Pharmaceuticals positions in Q1 2022 and 8 closed out, a net change of -3 holders.
- The largest Centessa Pharmaceuticals buyer in Q1 2022 was Medicxi Ventures Management, an estimated $16.8M added.
- The largest Centessa Pharmaceuticals seller in Q1 2022 was VR Adviser, an estimated $6.53M sold.
Based on aggregated 13F filings for Q1 2022.